No Data
No Data
Express News | Clover Biopharmaceuticals Ltd: Full Phase Ⅰ Data Readout Is Planned by Year-End 2024
Express News | Clover Biopharmaceuticals: Bivalent Scb-1019 Significantly Boosted Rsv-a and Rsv-B Neutralizing Antibody Titers in Older Adults
Express News | Clover Biopharmaceuticals Ltd: Study Showed Favorable Safety & Reactogenicity Profile Comparable to Saline Placebo
Express News | Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent Rsv Vaccine Candidate Scb-1019 in Older Adults
Adidas Bio-Tech (02197.HK) announced positive preliminary data from Phase I clinical trials of its bivalent RSV candidate vaccine SCB-1019 in elderly groups.
On June 18, Gelon Biotechnology-B (02197.HK) announced that in Phase I clinical trials evaluating the SCB-1019 bivalent RSV PreF-trimer subunit candidate vaccine developed based on Gelon Biotechnology's unique Trimer-Tag (protein trimerization) vaccine technology platform, positive preliminary immunogenicity and safety data were obtained in the elderly group. These preliminary data obtained in the elderly group (aged 60-85) are consistent with the positive data obtained in April this year in the young adult group (aged 18-59) announced by the company.
CLOVER BIO-B: 2023 Annual Report
No Data